{"id":"NCT00504075","sponsor":"Bio Products Laboratory","briefTitle":"A Study to Find How Safe and Effective GAMMAPLEX® is in Subjects With Chronic Idiopathic Thrombocytopenic Purpura (ITP)","officialTitle":"A Phase III, Multicenter, Open-Label Study To Evaluate the Efficacy and Safety of GAMMAPLEX® in Chronic Idiopathic Thrombocytopenic Purpura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-09","primaryCompletion":"2011-08","completion":"2011-08","firstPosted":"2007-07-19","resultsPosted":"2012-06-06","lastUpdate":"2013-03-01"},"enrollment":35,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Chronic Idiopathic Thrombocytopenic Purpura"],"interventions":[{"type":"BIOLOGICAL","name":"Gammaplex, intravenous immunoglobulin","otherNames":["Gammaplex"]}],"arms":[{"label":"Gammaplex (intravenous immunoglobulin)","type":"EXPERIMENTAL"}],"summary":"To determine if GAMMAPLEX raises the platelet count of subjects with chronic ITP to a threshold of 50 x 109/L, similar to that of published response \\>60%. Also to assess the safety of GAMMAPLEX and determine if platelet counts are maintained at 50 x 109/L in subjects with chronic ITP for.","primaryOutcome":{"measure":"The Number of Subjects With Chronic ITP Treated With Gammaplex Whose Platelet Count Reached a Threshold of 50 x 10^9/L.","timeFrame":"9 days","effectByArm":[{"arm":"GAMMAPLEX","deltaMin":29,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":30,"countries":["United States","Argentina","India"]},"refs":{"pmids":["24892422"],"seeAlso":["http://www.bpl.co.uk"]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":35},"commonTop":["Headache","Vomiting","Nausea","Petechiae","Pyrexia"]}}